Global Neurodegenerative Diseases Therapeutics Market Size Study, by Indication (Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Others) and Type (Mammography, Breast Ultrasound, Breast MRI, Image-guided Breast Biopsy,

Global Neurodegenerative Diseases Therapeutics Market Size Study, by Indication (Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Others) and Type (Mammography, Breast Ultrasound, Breast MRI, Image-guided Breast Biopsy, Other Imaging Techniques) and Regional Forecasts 2022-2032

Global Neurodegenerative Diseases Therapeutics Market is valued approximately at USD 52.05 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.51% over the forecast period 2024-2032. Neurodegenerative diseases therapeutics encompasses a broad spectrum of treatments aimed at managing and potentially curing diseases that progressively destroy brain cells, such as Alzheimer's, Parkinson's, and Huntington's diseases. These debilitating conditions result in a decline in cognitive, motor, and emotional functions, making the development of effective therapeutics critically important. The market's growth is driven by several factors, including a robust drug development pipeline bringing innovative treatments to various health conditions, particularly neurodegenerative diseases, and significant research funding dedicated to these conditions. Additionally, the availability of highly sensitive diagnostic modalities enhances early detection and diagnosis, improving patient outcomes and contributing to the market's expansion.

The market dynamics and customer landscape reveal that the residential sector is witnessing significant growth due to advancements in automatic cleaning technologies, particularly in the healthcare setting. Innovations in suction mechanisms, battery-powered and electric cleaning robots, and enhanced compatibility with Wi-Fi and app connectivity are transforming cleaning and maintenance in healthcare facilities. These innovations ensure thorough cleaning and sanitization, critical for environments dealing with neurodegenerative diseases. The increasing incidence of neurodegenerative diseases is a key driver of market growth. For instance, as per the Centers for Disease Control and Prevention (CDC), Alzheimer's disease affected around 6.2 million people in the US in 2021 and is expected to nearly triple to 14 million by 2060. The strong pipeline of drugs under development, such as ABT-SLV187 by AbbVie and APL-130277 by Sunovion, highlights the ongoing research and development efforts aimed at addressing these diseases. The introduction of new drugs and therapies is expected to drive market growth during the forecast period.

A significant market trend is the aging population, which is expected to nearly double from 12% to 22% between 2015 and 2050, according to the World Health Organization (WHO). This demographic shift increases the prevalence of neurodegenerative diseases, thereby driving demand for therapeutic interventions. In regions such as Sub-Saharan Africa, neurological disorders are commonly found in the elderly, further supporting market growth. One of the major challenges to market growth is the lack of disease-modifying therapies. While some neurodegenerative diseases, such as Alzheimer's and Parkinson's, have drugs that provide symptomatic relief, there are no approved therapies that impact the underlying disease processes for conditions like Huntington's disease. This gap in treatment options presents a significant challenge to market growth.

The key regions considered for the global Neurodegenerative Diseases Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Neurodegenerative Diseases Therapeutics Market in terms of revenue. The market growth in the region is being attributed to factors including rapidly aging population, increasing prevalence of neurological disorders like Alzheimer's and Parkinson's, substantial investments in research and development, and robust healthcare infrastructure. These factors contribute to a high demand for effective treatments and drive market growth. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rapidly aging population, increasing prevalence of neurological disorders, rising healthcare expenditure, and growing awareness about available treatments. These factors, coupled with the increasing penetration of western lifestyles and dietary habits, are contributing to the market's growth.

Major market players included in this report are:

AB Science SA

Acadia Pharmaceuticals Inc.

H Lundbeck AS

Mitsubishi Chemical Corp.

Novartis AG

Sanofi SA

Teva Pharmaceutical Industries Ltd.

Amgen Inc.

AstraZeneca PLC

Eli Lilly and Company

GlaxoSmithKline plc

Merck & Co., Inc.

AbbVie Inc.

Biogen Inc.

F. Hoffmann La Roche Ltd

The detailed segments and sub-segment of the market are explained below:

By Indication:
• Multiple sclerosis
• Alzheimer’s disease
• Parkinson’s disease
• Huntington’s disease
• Others

By Type:
• Mammography
• Breast ultrasound
• Breast MRI
• Image-guided breast biopsy
• Other imaging techniques

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico
• RoLA

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.